Needham Maintains Buy Rating on Starling Oncology, Raises Target to $9
Needham maintained its Buy rating and raised its price target to $9 per share from $7.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.